Cost, Value and Access of Personalized MedicineVideo Categories: Value
Anti-CTLA4 vs. Anti-PD-1
Dr. Sanjiv Agarwala examines the benefits of anti-PD-1 therapy vs. anti-CTLA4 therapy and how these therapies may be used on their own and in combination with each other in the future.
Integrating Cost into Treatment
According to Alexander Bastian, it’s very difficult to determine how to integrate cost into the equation of cancer care. He explains that cost should be considered early on and uses Dr. Zafar’s term of financial toxicity, meaning the burden of cost can be as bad or worse than a physical [ Read More ]